These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 27448505)

  • 1. Production of recombinant non-structural protein-3 hydrophobic domain deletion (NS3ΔHD) protein of bluetongue virus from prokaryotic expression system as an efficient diagnostic reagent.
    Mohanty NN; Chacko N; Biswas SK; Chand K; Pandey AB; Mondal B; Hemadri D; Shivachandra SB
    Biologicals; 2016 Sep; 44(5):352-9. PubMed ID: 27448505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An efficient production of hybrid recombinant protein comprising non-structural proteins (NS 1 & NS 3) of bluetongue virus in prokaryotic expression system.
    Mohanty NN; Shivachandra SB; Biswas SK; Nagaraj V; Basheer TJ; Narendra Babu D; Yogisharadhya R; Hemadri D
    Protein Expr Purif; 2019 Mar; 155():15-20. PubMed ID: 30217599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A DIVA system based on the detection of antibodies to non-structural protein 3 (NS3) of bluetongue virus.
    Barros SC; Cruz B; Luís TM; Ramos F; Fagulha T; Duarte M; Henriques M; Fevereiro M
    Vet Microbiol; 2009 Jun; 137(3-4):252-9. PubMed ID: 19233575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VP2-serotyped live-attenuated bluetongue virus without NS3/NS3a expression provides serotype-specific protection and enables DIVA.
    Feenstra F; Maris-Veldhuis M; Daus FJ; Tacken MG; Moormann RJ; van Gennip RG; van Rijn PA
    Vaccine; 2014 Dec; 32(52):7108-14. PubMed ID: 25454873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of recombinant NS1-NS3 antigen based indirect ELISA for detection of bluetongue antibodies in sheep.
    Mohanty NN; Hemadri D; Munivenkatarayappa A; Shetty N; Subramanyam V; Biswas SK; Chanda MM; Shivachandra SB
    J Immunol Methods; 2021 Mar; 490():112959. PubMed ID: 33412173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of bluetongue Disabled Infectious Single Animal (DISA) vaccine for different serotypes by VP2 exchange or incorporation of chimeric VP2.
    Feenstra F; Pap JS; van Rijn PA
    Vaccine; 2015 Feb; 33(6):812-8. PubMed ID: 25510389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A coiled-coil motif in non-structural protein 3 (NS3) of bluetongue virus forms an oligomer.
    Chacko N; Mohanty NN; Biswas SK; Chand K; Yogisharadhya R; Pandey AB; Mondal B; Shivachandra SB
    Virus Genes; 2015 Oct; 51(2):244-51. PubMed ID: 26318174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Bluetongue Disabled Infectious Single Animal (DISA) Vaccine Platform Based on Deletion NS3/NS3a Protein Is Safe and Protective in Cattle and Enables DIVA.
    van Rijn PA; Maris-Veldhuis MA; van Gennip RGP
    Viruses; 2021 May; 13(5):. PubMed ID: 34067226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prokaryotic expression of truncated VP7 of bluetongue virus (BTV) and reactivity of the purified recombinant protein with all BTV type-specific sera.
    Pathak KB; Biswas SK; Tembhurne PA; Hosamani M; Bhanuprakash V; Prasad G; Singh RK; Rasool TJ; Mondal B
    J Virol Methods; 2008 Sep; 152(1-2):6-12. PubMed ID: 18611412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bluetongue Virus NS4 Protein Is an Interferon Antagonist and a Determinant of Virus Virulence.
    Ratinier M; Shaw AE; Barry G; Gu Q; Di Gialleonardo L; Janowicz A; Varela M; Randall RE; Caporale M; Palmarini M
    J Virol; 2016 Jun; 90(11):5427-39. PubMed ID: 27009961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strong protection induced by an experimental DIVA subunit vaccine against bluetongue virus serotype 8 in cattle.
    Anderson J; Hägglund S; Bréard E; Riou M; Zohari S; Comtet L; Olofson AS; Gélineau R; Martin G; Elvander M; Blomqvist G; Zientara S; Valarcher JF
    Vaccine; 2014 Nov; 32(49):6614-21. PubMed ID: 25312275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a competitive ELISA for NS3 antibodies as DIVA test accompanying the novel Disabled Infectious Single Animal (DISA) vaccine for Bluetongue.
    Tacken MGJ; Daus FJ; Feenstra F; van Gennip RGP; van Rijn PA
    Vaccine; 2015 Oct; 33(42):5539-5545. PubMed ID: 26387435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of murine B-cell epitopes on bluetongue virus 12 nonstructural protein 1.
    HaiXiu W; EnCheng S; QingYuan X; Tao Y; Qin Z; YuFei F; JunPing L; Shuang L; Liang S; Jing S; DongLai W
    Appl Microbiol Biotechnol; 2015 Feb; 99(3):1309-21. PubMed ID: 25343975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective efficacy of Bluetongue virus-like and subvirus-like particles in sheep: presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection.
    Stewart M; Dovas CI; Chatzinasiou E; Athmaram TN; Papanastassopoulou M; Papadopoulos O; Roy P
    Vaccine; 2012 Mar; 30(12):2131-9. PubMed ID: 22285887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of plant-produced protein body vaccine candidates for bluetongue virus.
    van Zyl AR; Meyers AE; Rybicki EP
    BMC Biotechnol; 2017 May; 17(1):47. PubMed ID: 28558675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Competitive Enzyme-Linked Immunosorbent Assays for Antibody Detection Based on Bluetongue Virus Monoclonal Antibodies.
    Han Z; Mingxin Z; Xuechun L; Yigang X; Xinyuan Q; Li W; Wen C; Yanping J; Yijing L; Lijie T
    Viral Immunol; 2018 Apr; 31(3):264-271. PubMed ID: 29161226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and protective efficacy of recombinant major envelope protein (rH3L) of buffalopox virus in animal models.
    Kumar A; Yogisharadhya R; Venkatesan G; Bhanuprakash V; Shivachandra SB
    Antiviral Res; 2016 Feb; 126():108-16. PubMed ID: 26723250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production, characterization and assay application of a purified, baculovirus-expressed, serogroup specific bluetongue virus antigen.
    Luo L; Sabara MI
    Transbound Emerg Dis; 2008 May; 55(3-4):175-82. PubMed ID: 18405340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new form of particulate single and multiple immunogen delivery system based on recombinant bluetongue virus-derived tubules.
    Mikhailov M; Monastyrskaya K; Bakker T; Roy P
    Virology; 1996 Mar; 217(1):323-31. PubMed ID: 8599217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Virus-Host Protein Interactions of the Bluetongue Virus NS4 Virulence Factor.
    Fablet A; Kundlacz C; Dupré J; Hirchaud E; Postic L; Sailleau C; Bréard E; Zientara S; Vitour D; Caignard G
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.